LLY
Eli Lilly and Company
LLY has the edge over PTCT overall, supported by stronger fundamentals and stronger modeled upside.
PTCT
PTC Therapeutics, Inc.
PTCT's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PTCT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Strong |
PTCT's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PTCT PE Valuation
PTCT has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PTCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for PTCT, with profitability improving. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PTCT on earnings quality, reporting a profit while its opponent remains loss making.
PTCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.93 | — |
| Q3 2026 | -$1.36 | -116% |
| Q2 2026 | -$0.54 | -108% |
| Q1 2026 | -$2.29 | -135% |
| Q4 2025 | $7.78 | +$12.51 |
| Q3 2025 | $8.56 | +$14.51 |
| Q2 2025 | $6.97 | +$13.29 |
| Q1 2025 | $6.51 | +$14.20 |
| Q4 2024 | -$4.73 | +$3.64 |
PTCT has swung to a loss: it lost $1.36 per share over the past year, after a profit the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PTCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PTCT on profitability, with a higher operating margin.
PTCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $357.8M | +70% |
| Q2 2026 | $360.5M | +102% |
| Q1 2026 | $272.6M | -77% |
| Q4 2025 | $164.7M | -23% |
| Q3 2025 | $211M | +7.2% |
| Q2 2025 | $178.9M | -4.2% |
| Q1 2025 | $1.2B | +460% |
| Q4 2024 | $213.2M | -31% |
PTCT's revenue is recovering but still below its 2025 peak: $358M last quarter, up 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | +5.6 points |
| Q2 2026 | 41% | +61 points |
| Q1 2026 | 17% | -66 points |
| Q4 2025 | -43% | +33 points |
| Q3 2025 | 1.4% | +29 points |
| Q2 2025 | -20% | +2 points |
| Q1 2025 | 83% | +104 points |
| Q4 2024 | -76% | -78 points |
PTCT's operating margin was 7% last quarter, up 5.6 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
PTCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28M | +$41.8M |
| Q2 2026 | $126.9M | +$186.6M |
| Q1 2026 | -$60.2M | -107% |
| Q4 2025 | -$36.6M | -$2.9M |
| Q3 2025 | -$69.7M | +$7.8M |
| Q2 2025 | -$59.7M | +$4.4M |
| Q1 2025 | $868.4M | +1320% |
| Q4 2024 | -$33.8M | +$72.1M |
PTCT has burned cash in almost every quarter: $2M over the past year, down 100% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PTCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -9.3% | -8.5M shares |
| 1 year | -4.2% | -3.6M shares |
| 3 years | +11% | +8.1M shares |
| 5 years | +18% | +12.9M shares |
| Available history | +42% | +24.6M shares |
PTCT has the edge over LLY on shareholder dilution, with a more favorable share count trend.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PTCT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -2.5x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.6x | Net Cash |
| Q3 2024 | -15.8x | Net Cash |
| Q2 2024 | -51.7x | Net Cash |
PTCT has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PTCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 24.9 | Neutral |
PTCT's weekly RSI is 44 (neutral) and its Stochastic is 25 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PTCT PE vs Healthcare Sector
| Metric | PTCT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PTCT has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PTCT on trend strength, trading above more of its moving averages.
PTCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.4 | 1.5% above |
| 20 week MA | $68.8 | 7.9% below |
| 50 week MA | $70.9 | 11% below |
| 100 week MA | $62.3 | 1.7% above |
| 200 week MA | $49.1 | 29% above |
PTCT's trend is mixed: it's above three of its five weekly moving averages, and 29% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PTCT on returns for 2026, with the stronger performance.
PTCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.8 | $65.1 | +33% |
| 2021 | $65.1 | $41.9 | -36% |
| 2022 | $41.9 | $36.5 | -13% |
| 2023 | $36.5 | $27.6 | -24% |
| 2024 | $27.6 | $45.2 | +64% |
| 2025 | $45.2 | $78.6 | +74% |
| 2026 YTD | $78.6 | $63.4 | -19% |
PTCT has finished lower in three of the last six years. It's down 19% so far in 2026.